Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Chemo-immunotherapy followed by reduced-dose hypofractionated RT and durvalumab in unresectable stage III NSCLC
2024-518408-32-00Phase 2Authorised
- Sponsor
- IRCCS San Matteo Foundation
- Start
- Dec 2024
- Modality
- PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of durvalumab in non-small cell lung cancer (NSCLC), sponsored by IRCCS San Matteo Foundation. Primary endpoint: Grade 3 and Grade 4 PRAEs. Planned start Dec 2024; status: authorised.
02
Drugs
durvalumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2024-518408-32-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-518408-32-00.